Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge

Biomaterials

Volumn 33, Issue 35, 2012, Pages 9070-9079

  Chung, Seung Woo ^a   Lee, Myungjin ^b   Bae, Sang Mun ^c   Park, Jooho ^a   Jeon, Ok Cheol ^d   Lee, Hui Sun ^b   Choe, Han ^b   Kim, Han Sung ^f   Lee, Beom Suk ^b,e   Park, Rang Woon ^c   Kim, Sang Yoon ^b,e   Byun, Youngro ^a  

^a Seoul National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Korea Institute of Science and Technology   (South Korea)

^f Yonsei University Wonju   (South Korea)

Author keywords

Angiogenesis; Drug design; Low molecular weight heparin; Taurocholate; VEGF

Indexed keywords

ANGIOGENESIS; DRUG DESIGN; LOW-MOLECULAR WEIGHT HEPARINS; TAUROCHOLATE; VEGF;

ENDOTHELIAL CELLS; MOLECULES; SODIUM; SODIUM SULFATE; TUMORS;

POLYSACCHARIDES;

ANION; ANTITHROMBIN III; NADROPARIN; PENTASACCHARIDE; TAUROCHOLIC ACID; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ARTICLE; CELL STRAIN HT29; COLORECTAL CARCINOMA; CONJUGATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIONS; ANTICOAGULANTS; ANTITHROMBIN III; CELL LINE, TUMOR; HEPARIN, LOW-MOLECULAR-WEIGHT; HT29 CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOSACCHARIDES; TAUROCHOLIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867143259     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.002     Document Type: Article

References (35)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
2. Ferrara N., Hillan K.J., Gerber H.-P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400.
3. Capila I., Linhardt R.J. Heparin-protein interactions. Angew Chem 2002, 41(3):391-412.
4. Lever R., Page C. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002, 1(2):140-148.
5. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002, 2(7):521-528.
6. Mousa S.A., Linhardt R.J., Francis J.L., Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006, 96(6):816-821.
7. Pisano C., Aulicino C., Vesci L., Casu B., Naggi A., Torri G., et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005, 15(2):1C-6C.
8. Ritchie J.P., Ramani V.C., Ren Y., Naggi A., Torri G., Casu B., et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 2011, 17(6):1382-1393.
9. Kudchadkar R., Gonzalez R., Lewis K.D. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs 2008, 17(11):1769-1776.
10. Dredge K., Hammond E., Handley P., Gonda T.J., Smith M.T., Vincent C., et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011, 104(4):635-642.
11. Lee G.Y., Kim S.K., Byun Y. Glucosylated heparin derivatives as non-toxic anti-cancer drugs. J Control Release 2007, 123(1):46-55.
12. Park K., Kim Y.-S., Lee G.Y., Nam J.-O., Lee S.K., Park R.-W., et al. Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res 2007, 24(1):176-185.
13. Yu M.K., Lee D.Y., Kim Y.-S., Park K., Park S.A., Son D.H., et al. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm Res 2007, 24(4):705-714.
14. Park J.W., Jeon O.C., Kim S.K., Al-Hilal T.A., Jin S.J., Moon H.T., et al. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. J Control Release 2010, 148(3):317-326.
15. Lee E., Kim Y.-S., Bae S.M., Kim S.K., Jin S., Chung S.W., et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 2009, 124(12):2755-2765.
16. Fini A., Fazio G., Roda A., Bellini A.M., Mencini E., Guarneri M. Basic cholane derivatives. XI: comparison between acid and basic derivatives. J Pharm Sci 1992, 81(7):726-730.
17. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983, 79(2):926.
18. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998, 19(14):1639-1662.
19. Skinner R., Abrahams J.P., Whisstock J.C., Lesk A.M., Carrell R.W., Wardell M.R. The 2.6 A structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol 1997, 266(3):601-609.
20. Gasteiger J., Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron [Internet] 1980, 36(22):3219-3228.
21. Ersdal-Badju E., Lu A., Zuo Y., Picard V., Bock S.C. Identification of the antithrombin III heparin binding site. J Biol Chem 1997, 272(31):19393-19400.
22. Garcia-Sanz A., Rodriguez-Barbero A., Bentley M.D., Ritman E.L., Romero J.C. Three-dimensional microcomputed tomography of renal vasculature in rats. Hypertension 1998, 31(1 Pt 2):440-444.
23. Maehara N. Experimental microcomputed tomography study of the 3D microangioarchitecture of tumors. Eur Radiol 2003, 13(7):1559-1565.
24. Ferreira I.A., Mocking A.I.M., Urbanus R.T., Varlack S., Wnuk M., Akkerman J.-W.N. Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B. J Biol Chem 2005, 280(38):32625-32633.
25. Robinson C.J., Mulloy B., Gallagher J.T., Stringer S.E. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem 2006, 281(3):1731-1740.
26. Krilleke D., DeErkenez A., Schubert W., Giri I., Robinson G.S., Ng Y.-S., et al. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J Biol Chem 2007, 282(38):28045-28056.
27. Lindahl U., Bäckström G., Höök M., Thunberg L., Fransson L.A., Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci U S A 1979, 76(7):3198-3202.
28. Bishop J.R., Schuksz M., Esko J.D. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 2007, 446(7139):1030-1037.
29. Ono K., Hattori H., Takeshita S., Kurita A., Ishihara M. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology 1999, 9(7):705-711.
30. Cate ten H., Lamping R.J., Henny C.P., Prins A., Cate ten J.W. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. Clin Chem 1984, 30(6):860-864.
31. Esko J.D., Selleck S.B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002, 71:435-471.
32. Verheul H.M.W., Lolkema M.P.J., Qian D.Z., Hilkes Y.H.A., Liapi E., Akkerman J.-W.N., et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007, 13(18 Pt 1):5341-5347.
33. Verheul H.M.W., Hoekman K., Luykx-de Bakker S., Eekman C.A., Folman C.C., Broxterman H.J., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3(12 Pt 1):2187-2190.
34. Weltermann A., Wolzt M., Petersmann K., Czerni C., Graselli U., Lechner K., et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999, 19(7):1757-1760.
35. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10(1):9-22.